Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

The European Medicines Agency’s, EMA, committee recommended a change to extend the use of Eli Lilly’s (LLY) Mounjaro for the treatment of type 2 ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Regulators voted Thursday to extend a shutdown preventing New England fishermen from catching shrimp, a historic industry ...